Elisabetta Bolli
5PUBLICATIONS
22CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Apr 14, 2026
Tumor microenvironment remodeling by STING agonism sensitizes endothelial cells to cytotoxic anti-PD-L1/L2 antibody.Ahmad Salameh, Elisabetta Bolli, Manuela Iezzi
|Nov 11, 2022
Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models.Giuseppina Barutello, Antonino Di Lorenzo, Alessandro Gasparetto
|Jun 27, 2022
Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy.Antonino Di Lorenzo, Elisabetta Bolli, Roberto Ruiu
|Dec 16, 2020
Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota.Antonino Di Lorenzo, Elisabetta Bolli, Lidia Tarone
|Dec 08, 2018
Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells.Gaetano Donofrio, Giulia Tebaldi, Stefania Lanzardo
Pageof 1
Frequent Collaborators
5 joint publications
Laura Conti
5 joint publications
Federica Cavallo
3 joint publications
Antonino Di Lorenzo
2 joint publications
Roberto Ruiu
1 joint publications
Gaetano Donofrio
1 joint publications
Valeria Rolih
1 joint publications
Giuseppe Ferrauto
1 joint publications
Enza Di Gregorio
1 joint publications
Lidia Avalle
1 joint publications
Aurora Savino
